MedTrace Logo

Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis

NCT02045277 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 212

Last updated 2020-08-20

Study results available
· View outcomes & findings →

Summary

The objective of the study is to evaluate the safety and efficacy of a topical lotion

Conditions

Interventions

DRUG

IDP-118 Lotion

Lotion

DRUG

IDP-118 Monad HP Lotion

Active Comparator

DRUG

IDP-118 Monad Taz Lotion

Active Comparator

DRUG

IDP-118 Vehicle Lotion

Vehicle

Sponsors & Collaborators

  • Dow Pharmaceutical Sciences

    collaborator INDUSTRY

  • Bausch Health Americas, Inc.

    lead INDUSTRY

Principal Investigators

  • Binu J Alexander · Valeant Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2014-11-30
Completion
2014-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02045277 on ClinicalTrials.gov